Open-Label Extension Protocol to SNK01-AD01 Study
Recruiting
Phase 2
Interventional Study
Alzheimer Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 40 – 85
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- NKGen Biotech, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Open-Label Extension Protocol to SNK01-AD01 Study
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Participants will be considered eligible for participation in the study if all the following criteria are satisfied:
* The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements …
Contacts